Thus, the antihypertensive effect via the ACE inhibitory activity of a DPP4 inhibitory peptide is expected to be beneficial for the management of T2D patients with hypertension, as well as for hypertension patients with T2D. This evidence concerns the gene DPP4 and hypertensive disorder.